Vivani Medical, Inc. (VANI) research
Vivani Medical, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.23
- As of
Vivani Medical, Inc. (VANI): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-16.
As of . Source: SEC EDGAR filings for VANI. Method and limitations.
Share the VANI intelligence card
See the full VANI dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for VANI on one page. Preview it with sample data, then open it live with a free account.
Preview the VANI dossierActive signals for VANI
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 17.6%, EPS $-0.07 vs $-0.085 estimate
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 62% of VANI (2026Q1)
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 17.6% - EPS $-0.12 vs $-0.102 estimate
- mediumEARNINGS_BEAT
Q4-2025: Beat consensus by 11.8% - EPS $-0.09 vs $-0.102 estimate
- mediumEARNINGS_MISS
Missed consensus by 17.6% - EPS $-0.12 vs $-0.102 estimate
FREE, NO ACCOUNT
Every signal on VANI, as it fires
You are seeing 5 of 6 signals recorded on VANI since 2026-05-29.
The five above landed across 4 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.
Recent SEC filings, VANI
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
VANI mentioned in Kresmion daily briefs
VANI against its peers
VANI's return on equity of -169.2% ranks in the 22nd percentile of 19 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-01-31.
| Metric | VANI | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 2.0M USD | 13 | 15 |
| Operating margin | n/a | -442.9% | n/a | 12 |
| Net margin | n/a | -430.3% | n/a | 13 |
| Return on equity | -169.2% | -78.3% | 23 | 19 |
Peers (23): LENZ, CBUS, GNLX, OKUR, AARD, COYA, IMUX, BDTX, UNCY, PYPD, CRBP, VXRT, EQ, FHTX, KZIA, VTVT, INO, HURA, MNOV, NRXP, MIST, TNYA, NTRB. Left out: SPRC (period gap), CNXU (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-01-31. Every figure is one full fiscal year read from one annual filing (VANI: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more VANI signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to VANIand get the insider, 13F, options, and confluence read in one view.